Genzyme’s alemtuzumab treatment for multiple sclerosis has been granted Fast Track status by the FDA. This designation covers patients with relapsing-remitting forms of the disease. The Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. It makes alemtuzumab for MS eligible for Priority Review and the FDA may consider for review portions of the m...